BELGRADE, Mont., June 3, 2015 (GLOBE NEWSWIRE) — Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary biomaterials, today announced the release of ArthroFuse, a patent pending allograft specifically designed for the treatment of hammertoe deformities.
Hammertoe deformity affects the proximal interphalangeal joint of the lesser metatarsals and often resulting in debilitating joint pain and disability. While 550,000 surgical hammertoe procedures are performed each year in the United States it is thought that the majority of an estimated 60 million affected adults go undiagnosed. “We are excited to announce the launch of ArthroFuse, the newest addition to our regenerative biologics portfolio,” said Gregory Juda PhD, CSO. “We developed this product in response to the needs of our surgeon end users to allow them to successfully treat this commonly painful pathology.”
Current surgical options include screws, staples, pins and intermedulary implants. Bacterin’s novel approach to this affliction eliminates the need for externally communicating pins or permanent implants by providing an implant that will remodel over time into the patient’s own bone. ArthroFuse is an addition to Bacterin’s allograft catalog, specifically targeted to foot and ankle surgeons active in the $500 million to $1 billion (est) Hammertoe implant market.
